Peptide Access Index
As of October 12, 2026 · 210 rows
The Peptide Access Index lists 210 rows with their FDA, 503A compounding, PCAC and WADA 2026 status as of October 4–12, 2026. Each row links its primary sources.
Get updates on the Peptide Access Index
Showing 210 of 210 rows
Status labels
- FDA-approved (Rx)
- Not FDA-approved for this use
- Not FDA-approved · advisory vote, no FDA decision
- Investigational
- Not FDA-approved
- FDA-approved, discontinued
- Approved outside the US
- Supplement
- Cosmetic
Color is only a cue; the label and icon carry the status. How we label status
Scroll sideways to see all columns.
| Name | Status How we label status | FDA status | 503A compounding | PCAC history | WADA 2026 | As of | Sources |
|---|---|---|---|---|---|---|---|
| 5-Amino-1MQ5-amino-1mq, 5 amino 1mq, 5-amino-1-methylquinolinium | Not FDA-approved | Not FDA-approved | No category; not on 216.23 as of 2026-10-07; not an approved-drug component (as of October 7, 2026) | Not recorded | Not recorded | ||
| Abaloparatideabaloparatide, tymlos | FDA-approved (Rx) | Approved Rx (Tymlos NDA208743, 2017) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Acarboseacarbose, precose, glucobay | FDA-approved (Rx) | Approved Rx (Precose NDA020482 1995, disc.; generics); label: type 2 diabetes | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not named | ||
| Adamax (adamantane semax)adamax peptide, adamax, super semax | Not FDA-approved | Not FDA-approved (no drugsfda/DailyMed record) | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not named; S0 (non-approved substances) applies if no health authority approves it for human use | ||
| Afamelanotideafamelanotide, scenesse, melanotan 1, melanotan i | FDA-approved (Rx) | Approved Rx (Scenesse NDA210797, 2019) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| AHK-Cu (copper tripeptide)ahk-cu, ahk cu, ahk-cu peptide | Not FDA-approved | Not FDA-approved (no drugsfda record) | No category; not on 216.23 as of 2026-10-07; not an approved-drug component (as of October 7, 2026) | Not recorded | Not named; S0 (non-approved substances) applies if no health authority approves it for human use | ||
| Alanyl-L-glutaminealanyl-l-glutamine, alanyl glutamine, l-alanyl-l-glutamine | Not FDA-approved | Not FDA-approved (as a drug) | Category 1 (interim; enforcement discretion); not on 216.23 as of 2026-10-07 (as of October 7, 2026) | 2015-10-27/28: voted not to include (vote count not confirmed), FDA proposed exclusion 2019-09-05, never finalized | Not recorded | ||
| Amycretinamycretin, nnc0487-0111 | Investigational (phase 3) | Investigational, phase 3 started 2026 (AMAZE), not filed | No category; not on 216.23 as of 2026-10-07; not an approved-drug component (as of October 7, 2026) | Not recorded | Not recorded | ||
| Anastrozoleanastrozole, arimidex, adex, anastrazole | FDA-approved (Rx) | Approved Rx (Arimidex NDA020541 1995; generics); label: breast cancer in postmenopausal women. Use in men is off-label | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | S4.1 (named Anastrozole) | ||
| AOD-9604aod-9604, aod 9604, aod9604, hgh fragment 176-191, hgh frag | Not FDA-approved | Not FDA-approved | No category (nomination withdrawn; removed from Cat 2 2024-09-27); not on 216.23 as of 2026-10-07; not an approved-drug component (as of October 7, 2026) | 2024-12-04: against 0-12-0 (group vote; use reviewed: obesity); FDA staff: against | S2.2.3 | ||
| Argireline (acetyl hexapeptide-8)argireline, acetyl hexapeptide-8, acetyl hexapeptide-3 | Cosmetic | Cosmetic | Not recorded | Not recorded | Not recorded | ||
| Berberineberberine, berberine hcl, berberine hydrochloride, natural ozempic, nature's ozempic | Supplement | Not an approved drug; sold as a dietary supplement (no FDA statement that it is unlawful found) | Not recorded | Not recorded | Not named on the 2026 List | ||
| Bivalirudinbivalirudin, angiomax | FDA-approved (Rx) | Approved Rx (Angiomax NDA020873, 2000) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| BPC-157bpc 157, bpc-157, bpc157, body protection compound, pentadecapeptide bpc 157, bpc | Not FDA-approved · advisory vote July 2026 · no FDA decision | Not FDA-approved | No category since 2026-04-22 (nomination withdrawn); PCAC recommended 2026-07-23/24; no proposed rule as of 2026-10-04 (as of October 4, 2026) | 2026-07-23: recommended 8-6-1 (free base and acetate; use reviewed: ulcerative colitis; count as read into FDA's meeting recording; written minutes not posted as of 2026-10-04); FDA staff: against | S0 | ||
| BPC-157 / GHK-Cu stackbpc ghk-cu, bpc-157 ghk-cu | Not FDA-approved | Not FDA-approved as a combination | No category as a combination (see components) | Not recorded | Not recorded | ||
| BPC-157 / KPV stackbpc kpv, bpc-157 kpv | Not FDA-approved | Not FDA-approved as a combination | No category as a combination (see components) | Not recorded | Not recorded | ||
| BPC-157 / thymosin alpha-1 stackbpc-157 thymosin alpha-1, bpc ta1 | Not FDA-approved | Not FDA-approved as a combination | No category as a combination (see components) | Not recorded | Not recorded | ||
| Bremelanotidebremelanotide, pt-141, pt 141, pt141 | FDA-approved (Rx) | Approved Rx (Vyleesi, NDA210557, 2019) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Bremelanotide / oxytocin / kisspeptin-10 stacklibido peptide stack, pt-141 oxytocin, sexual optimization blend | Not FDA-approved | Not FDA-approved as a combination | No category as a combination (see components) | Not recorded | Not recorded | ||
| Bronchogenbronchogen, ala-glu-asp-leu | Not FDA-approved | Not FDA-approved (no drugsfda/DailyMed record) | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not named; S0 (non-approved substances) applies if no health authority approves it for human use | ||
| Cagrilintidecagrilintide, cagri, cagrilintide peptide | Investigational (phase 3) | Investigational, not filed as monotherapy | Not eligible (FDA: 'cannot be used in compounding under federal law') (as of October 1, 2026) | Not recorded | Not recorded | ||
| Cagrilintide / retatrutide stackcagri reta, cagri reta stack, cagrilintide retatrutide | Not FDA-approved | Not FDA-approved as a combination | No category as a combination (see components) | Not recorded | Not recorded | ||
| Cagrilintide / tirzepatide stackcagri tirz, cagrilintide tirzepatide | Not FDA-approved | Not FDA-approved as a combination | No category as a combination (see components) | Not recorded | Not recorded | ||
| CagriSema (cagrilintide + semaglutide)cagrisema, cagri sema, cagrilintide semaglutide | Not FDA-approved | Investigational; NDA submitted 2025-12-18 (sponsor), FDA decision pending | Not eligible (cagrilintide component: FDA 'cannot be used in compounding') (as of October 1, 2026) | Not recorded | Not recorded | ||
| Calcitonin salmoncalcitonin, calcitonin salmon, miacalcin | FDA-approved (Rx) | Approved Rx (Miacalcin injection NDA017808, 1986; nasal forms Disc) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Cardarine (GW501516)cardarine, gw501516, gw-501516, gw 501516, gw1516, endurobol | Not FDA-approved | Not FDA-approved; FDA WL 719257 calls 'Cardarine GW501516' an unapproved new drug | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | S4.4.1 (PPAR-delta agonists; named GW1516, GW501516) | ||
| Cardiogen (peptide bioregulator)cardiogen peptide, cardiogen | Not FDA-approved | Not FDA-approved (no drugsfda/DailyMed record) | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not named; S0 (non-approved substances) applies if no health authority approves it for human use | ||
| Cartalaxcartalax, cartalax peptide | Not FDA-approved | Not FDA-approved (no drugsfda/DailyMed record) | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not named; S0 (non-approved substances) applies if no health authority approves it for human use | ||
| Cerebrolysincerebrolysin, cerebrolysine, fpf-1070 | Approved outside the US | Not FDA-approved (no drugsfda/DailyMed record) | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not named; approved in Austria and Russia, so S0 does not apply | ||
| Cetrorelixcetrorelix, cetrotide | FDA-approved (Rx) | Approved Rx (Cetrotide NDA021197, 2000) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Chonlutenchonluten, honluten | Not FDA-approved | Not FDA-approved (no drugsfda/DailyMed record) | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not named; S0 (non-approved substances) applies if no health authority approves it for human use | ||
| Cibinetide (ARA-290)cibinetide, ara-290, ara 290 | Not FDA-approved | Not FDA-approved | Category 3 (since 2023-09-29); not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not recorded | ||
| CJC-1295cjc-1295, cjc 1295, cjc1295, cjc-1295 dac, cjc 1295 no dac, mod grf 1-29 | Not FDA-approved | Not FDA-approved | No category (nomination withdrawn; removed from Cat 2 2024-09-27); not on 216.23 as of 2026-10-07; not an approved-drug component (as of October 7, 2026) | 2024-12-04: against (free base 0-13; acetate 1-12; DAC forms 0-13 each; use reviewed: GHD); FDA staff: against | S2.2.4 | ||
| CJC-1295 / ipamorelin / GHRP-2 blendmod grf ipamorelin ghrp-2, cjc ipamorelin ghrp-2 blend, gh triple blend | Not FDA-approved | Not FDA-approved as a combination | No category as a combination (see components) | Not recorded | Not recorded | ||
| CJC-1295 / ipamorelin stackcjc ipamorelin, cjc/ipamorelin, cjc ipa stack, cjc-1295 ipamorelin blend | Not FDA-approved | Not FDA-approved | Neither component has a 503A category (both withdrawn 2024-09-27); ipamorelin acetate is in 503B Category 2 (as of May 14, 2026) | Components each voted against: ipamorelin 2024-10-29, CJC-1295 2024-12-04 | S2.2.4 | ||
| Clomiphene (clomiphene citrate)clomiphene, clomiphene citrate, clomid, clomifene, serophene, clomid for men | FDA-approved (Rx) | Approved Rx (Clomid NDA016131 1967, now ANDA075528; generics); label: ovulatory dysfunction in women. Male use is off-label | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | S4.2 (named Clomifene) | ||
| Collagen peptides (hydrolyzed collagen)collagen peptides, hydrolyzed collagen, collagen powder, collagen supplement | Supplement | Food / dietary supplement | Not recorded | Not recorded | Not recorded | ||
| Compounded semaglutidecompounded semaglutide, compounded ozempic, compounded wegovy, semaglutide b12 | Not FDA-approved | Not FDA-approved (compounded drugs are not FDA-approved) | Shortage resolved 2025-02-21; 503A only if not 'essentially a copy' (documented prescriber determination) or <=4 Rx/month; not on 503B bulks or shortage list (as of April 1, 2026) | Not recorded | Not recorded | ||
| Compounded tirzepatidecompounded tirzepatide, compounded mounjaro, compounded zepbound | Not FDA-approved | Not FDA-approved (compounded drugs are not FDA-approved) | Shortage resolved 2024-12-19; 503A only if not 'essentially a copy' (documented prescriber determination) or <=4 Rx/month; not on 503B bulks or shortage list (as of April 1, 2026) | Not recorded | Not recorded | ||
| CoQ10 / ubiquinolcoq10, coenzyme q10, ubiquinol, ubiquinone | Supplement | Dietary supplement (DSHEA) | Not recorded | Not recorded | Not recorded | ||
| Cortagen (peptide bioregulator)cortagen, cortagen peptide | Not FDA-approved | Not FDA-approved (no drugsfda/DailyMed record) | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not named; S0 (non-approved substances) applies if no health authority approves it for human use | ||
| Cortexincortexin, cortexine, korteksin | Approved outside the US | Not FDA-approved (no drugsfda/DailyMed record) | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not named; approved in Russia, so S0 does not apply | ||
| Creatine monohydratecreatine, creatine monohydrate, creapure | Supplement | Dietary supplement (DSHEA) | Not recorded | Not recorded | Not recorded | ||
| Crystagencrystagen, kristagen | Not FDA-approved | Not FDA-approved (no drugsfda/DailyMed record) | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not named; S0 (non-approved substances) applies if no health authority approves it for human use | ||
| Dalargindalargin, tyr-d-ala-gly-phe-leu-arg | Approved outside the US | Not FDA-approved (no drugsfda/DailyMed record) | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not named; approved in Russia, so S0 does not apply | ||
| Dasiglucagondasiglucagon, zegalogue | FDA-approved (Rx) | Approved Rx (Zegalogue NDA214231, 2021); Drugs@FDA lists both products Discontinued; the only US listing (Novo Nordisk) has a marketing end date of 2027-08-31 | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Degarelixdegarelix, firmagon | FDA-approved (Rx) | Approved Rx (Firmagon NDA022201, 2008) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Desmopressindesmopressin, ddavp, desmoda | FDA-approved (Rx) | Approved Rx (DDAVP NDA019955; Desmoda 2026) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | S5 | ||
| DHEA (dehydroepiandrosterone, prasterone)dhea, dehydroepiandrosterone, prasterone, dhea supplement, dhea cream | FDA-approved (Rx) | Approved Rx as prasterone (Intrarosa NDA208470, 2016; vaginal insert for menopausal dyspareunia); also sold OTC as a supplement | Approved-drug component (503B Category 1 '**') (as of May 14, 2026) | Not recorded | S1.1 (named prasterone/DHEA) | ||
| Difelikefalindifelikefalin, korsuva | FDA-approved (Rx) | Approved Rx (Korsuva NDA214916, 2021) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Dihexadihexa, dihexa acetate, pnb-0408 | Not FDA-approved | Not FDA-approved | No category (nomination withdrawn; removed from Cat 2 2026-04-22); not on 216.23 as of 2026-10-07; not an approved-drug component (as of October 7, 2026) | Scheduled: PCAC 'before the end of February 2027' (no date set) | Not recorded | ||
| Dulaglutidedulaglutide, trulicity | FDA-approved (Rx) | Approved Rx (Trulicity BLA125469, 2014) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Egriftaegrifta, egrifta sv, egrifta wr | FDA-approved (Rx) | Approved Rx (BLA022505, 2010; current Egrifta WR and SV; HIV lipodystrophy abdominal fat) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Elamipretideelamipretide, ss-31, ss 31, ss31 | FDA-approved (Rx) | Approved Rx (Forzinity NDA215244, 2025-09-19, accelerated approval) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Eloralintideeloralintide, eloralintide peptide, ly3841136 | Investigational (phase 3) | Investigational, phase 3 (Eli Lilly); no FDA approval record | No category; not on 216.23 as of 2026-10-07; not an approved-drug component (as of October 7, 2026) | Not recorded | Not recorded | ||
| Emideltide (DSIP)dsip, delta sleep inducing peptide, emideltide, delta sleep-inducing peptide | Not FDA-approved | Not FDA-approved | No category (nomination withdrawn; removed from Cat 2 2026-04-22); not on 216.23 as of 2026-10-07; not an approved-drug component (as of October 7, 2026) | 2026-07-24: NOT recommended 6-7-1 (free base and acetate; uses reviewed: opioid withdrawal, chronic insomnia, narcolepsy; count as read into FDA's meeting recording; written minutes not posted as of 2026-10-04); FDA staff: against | Not recorded | ||
| Enclomiphene (enclomiphene citrate)enclomiphene, enclomiphene citrate, enclomifene, androxal, enclomid | Not FDA-approved | Not FDA-approved (openFDA: no application) | Category 1 (503A, interim); FDA proposed NOT listing it and PCAC voted 4-8 against (2022-06-08); FDA: not an approved-drug component. Not in 503B; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | PCAC 2022-06-08: 4-8 against; FDA staff: against | S4.2 by class (SERMs; not named) | ||
| Epitalonepitalon, epithalon, epithalone, ala-glu-asp-gly, aedg | Not FDA-approved · advisory vote July 2026 · no FDA decision | Not FDA-approved | No category since 2026-04-22 (nomination withdrawn); PCAC recommended 2026-07-23/24; no proposed rule as of 2026-10-04 (as of October 4, 2026) | 2026-07-24: recommended 7-4-1 (free base and acetate; use reviewed: insomnia; count as read into FDA's meeting recording; written minutes not posted as of 2026-10-04); FDA staff: against | Not recorded | ||
| Epitalon / GHK-Cu stack | Not FDA-approved | Not FDA-approved as a combination | No category as a combination (see components) | Not recorded | Not recorded | ||
| Epitalon / pinealon stackepitalon pinealon, epithalon pinealon | Not FDA-approved | Not FDA-approved as a combination | No category as a combination (see components) | Not recorded | Not recorded | ||
| Epitalon / thymalin stackepitalon thymalin, khavinson stack | Not FDA-approved | Not FDA-approved as a combination | No category as a combination (see components) | Not recorded | Not recorded | ||
| Epithalamin (pineal extract)epithalamin, epithalamine, epitalamin | Not FDA-approved | Not FDA-approved (no drugsfda/DailyMed record) | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not named; S0 (non-approved substances) applies if no health authority approves it for human use | ||
| Estradiolestradiol, oestradiol, estrace, estradiol patch, climara, vivelle-dot, estradiol cypionate, estradiol valerate, estradiol cream, estradiol gel, divigel, vagifem, estring, bioidentical estrogen | FDA-approved (Rx) | Approved Rx (Climara NDA020375; Estrace ANDA086069; Depo-Estradiol ANDA085470; hundreds of products); label: menopausal vasomotor symptoms, vulvar/vaginal atrophy, hypoestrogenism. Boxed warning | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not named | ||
| Exenatideexenatide, byetta, bydureon, bydureon bcise | FDA-approved (Rx) | Approved Rx (Byetta NDA021919 listed Rx; NDA021773 Disc; Bydureon/BCise Disc) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Finasteridefinasteride, propecia, proscar, topical finasteride | FDA-approved (Rx) | Approved Rx (Proscar NDA020180 1992, BPH; Propecia NDA020788 1997, male pattern hair loss, men only); no approved topical found | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not named | ||
| Fisetinfisetin | Supplement | Not an approved drug; sold as a dietary supplement | Not recorded | Not recorded | Not named | ||
| Follistatinfollistatin, follistatin 344, fs-344 | Not FDA-approved | Not FDA-approved | No category; not on 216.23 as of 2026-10-07; not an approved-drug component (as of October 7, 2026) | Not recorded | S4.3 | ||
| Forzinityforzinity | FDA-approved (Rx) | Approved Rx (NDA215244, 2025-09-19, accelerated approval; Barth syndrome) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Foundayofoundayo | FDA-approved (Rx) | Approved Rx (NDA220934, 2026-04-01) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| FOXO4-DRIfoxo4-dri, foxo4 dri, foxo4-dri peptide | Not FDA-approved | Not FDA-approved (no drugsfda record) | No category; not on 216.23 as of 2026-10-07; not an approved-drug component (as of October 7, 2026) | Not recorded | Not named; S0 (non-approved substances) applies if no health authority approves it for human use | ||
| Ganirelixganirelix, antagon | FDA-approved (Rx) | Approved Rx (ganirelix acetate NDA021057, 1999) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| GH triple stack (CJC-1295 + ipamorelin + sermorelin)growth hormone triple stack, gh triple stack | Not FDA-approved | Not FDA-approved as a combination | No category as a combination (see components) | Not recorded | Not recorded | ||
| GHK-Cu (copper tripeptide)ghk-cu, ghk cu, copper peptide, copper tripeptide-1, glycyl-l-histidyl-l-lysine copper | Cosmetic | Not FDA-approved as a drug; cosmetic ingredient (topical) | Non-injectable: Category 1 (removed 2026-04-22; 'will be added back'); injectable: no category (as of May 14, 2026) | Scheduled: PCAC 'before the end of February 2027' (no date set) | Not recorded | ||
| GHK-Cu (injectable)ghk-cu injection, ghk-cu injectable, copper peptide injection, ghk cu vial | Not FDA-approved | Not FDA-approved | No category (nomination withdrawn; removed from Cat 2 2026-04-22); not on 216.23 as of 2026-10-07; not an approved-drug component (injectable routes) (as of October 7, 2026) | Scheduled: PCAC 'before the end of February 2027' (no date set) | Not recorded | ||
| GHK-Cu (topical cosmetic)ghk-cu serum, ghk-cu cream, copper peptide serum | Cosmetic | Cosmetic (not a drug when sold with appearance claims) | Category 1 for non-injectable compounding (removed 2026-04-22; FDA says 'will be added back', 2026-05-14 PDF) (as of May 14, 2026) | Scheduled: PCAC 'before the end of February 2027' (no date set) | Not recorded | ||
| GHK-Cu / thymulin / PTD-DBM stackhair growth peptide stack, hair peptide stack | Not FDA-approved | Not FDA-approved as a combination | No category as a combination (see components) | Not recorded | Not recorded | ||
| GHRP-2 (pralmorelin)ghrp-2, ghrp 2, ghrp2, pralmorelin | Not FDA-approved | Not FDA-approved | Category 3; 503B Category 2 (injectable/nasal), 503B Category 1 (other routes); not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | S2.2.4 | ||
| GHRP-6ghrp-6, ghrp 6, ghrp6 | Not FDA-approved | Not FDA-approved | Category 3; 503B Category 2 (since 2023-09-29); not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | S2.2.4 | ||
| GLOW blend (GHK-Cu + BPC-157 + TB-500)glow peptide, glow blend, glow stack, glow peptide blend | Not FDA-approved | Not FDA-approved | Contains GHK-Cu injectable (no category; withdrawn 2026-04-22) (as of May 14, 2026) | Not recorded | S0 (BPC-157); S2.3 (TB-500) | ||
| Glucagonglucagon, gvoke, baqsimi, glucagon kit | FDA-approved (Rx) | Approved Rx (Lilly NDA012122 1960; Gvoke NDA212097; Baqsimi) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Glutathioneglutathione, gsh, l-glutathione, reduced glutathione | Supplement | Dietary supplement (DSHEA) when oral; injectable is the glutathione-injectable row | Category 1 (503A, injectable compounding) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Glutathione (injectable/IV)glutathione injection, iv glutathione, glutathione iv, glutathione push, gsh injection | Not FDA-approved | Not FDA-approved | Category 1 (interim; enforcement discretion); 503B Category 1 (as of May 14, 2026) | 2022-06-08: 8-5-1 in favor of inclusion (no rule since); FDA staff: against | Not recorded | ||
| Glutathione (oral)oral glutathione, liposomal glutathione | Supplement | Dietary supplement (DSHEA) | Not recorded | Not recorded | Not recorded | ||
| Glycineglycine | Supplement | Dietary supplement (DSHEA) | Not recorded | Not recorded | Not recorded | ||
| GlyNAC (glycine + NAC)glynac, glycine nac | Supplement | Dietary supplement under FDA enforcement discretion (NAC) | Not recorded | Not recorded | Not recorded | ||
| Gonadorelingonadorelin, factrel, lutrepulse, gnrh, gonadorelin acetate | FDA-approved, discontinued | Approved for people as Factrel in 1982 and Lutrepulse in 1989. Both have since been discontinued. The federal drug label site DailyMed lists gonadorelin only in drugs for animals | No 503A category; 503B Category 1 as approved-drug component (as of March 21, 2025) | Not recorded | S2.2.1 (males) | ||
| Goserelingoserelin, zoladex | FDA-approved (Rx) | Approved Rx (Zoladex NDA019726, 1989) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | S2.2.1 (males) | ||
| Hexarelin (examorelin)hexarelin, examorelin | Not FDA-approved | Not FDA-approved | No category; not on 216.23 as of 2026-10-07; not an approved-drug component (as of October 7, 2026) | Not recorded | S2.2.4 | ||
| Human chorionic gonadotropin (hCG)hcg, chorionic gonadotropin, novarel, pregnyl, human chorionic gonadotropin | FDA-approved (Rx) | Approved Rx (Novarel, Pregnyl; current DailyMed labels) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | S2.2.1 (males) | ||
| Ibutamoren (MK-677)ibutamoren, mk-677, mk 677, mk677, ibutamoren mesylate | Not FDA-approved | Not FDA-approved | Category 2 (since 2023-09-29); 503B Category 2 (since 2022-12-29); not on 216.23 as of 2026-10-07 (as of October 7, 2026) | 2024-10-29: against 1-13-0; FDA staff: against | S2.2.4 | ||
| Icatibanticatibant, firazyr | FDA-approved (Rx) | Approved Rx (Firazyr NDA022150, 2011; generics) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| IGF-1 LR3igf-1 lr3, igf1 lr3, igf-1lr3, long r3 igf-1 | Not FDA-approved | Not FDA-approved | No category; not on 216.23 as of 2026-10-07; not an approved-drug component (as of October 7, 2026) | Not recorded | S2.3 | ||
| Ipamorelinipamorelin, ipamorelin acetate, ipa | Not FDA-approved | Not FDA-approved | No category (nomination withdrawn; removed from Cat 2 2024-09-27); not on 216.23 as of 2026-10-07; not an approved-drug component; 503B Category 2 (as of October 7, 2026) | 2024-10-29: against 0-12-1 (free base and acetate; uses reviewed: GHD, postoperative ileus); FDA staff: against | S2.2.4 | ||
| Kisspeptin-10kisspeptin, kisspeptin-10, kisspeptin 10, kp-10 | Not FDA-approved | Not FDA-approved | Category 2 (since 2023-09-29); not on 216.23 as of 2026-10-07 (as of October 7, 2026) | 2024-10-29: against 0-11-0 (use reviewed: male secondary hypogonadism); FDA staff: against | S2.2.1 (males) | ||
| Klotho (protein)klotho, klotho peptide, klotho protein | Not FDA-approved | Not FDA-approved (no drugsfda record) | No category; not on 216.23 as of 2026-10-07; not an approved-drug component (as of October 7, 2026) | Not recorded | Not named; S0 (non-approved substances) applies if no health authority approves it for human use | ||
| KLOW blendklow peptide, klow blend, klow stack | Not FDA-approved | Not FDA-approved | Contains GHK-Cu injectable (no category; withdrawn 2026-04-22) (as of May 14, 2026) | Not recorded | Not recorded | ||
| KPVkpv, kpv peptide, lys-pro-val, alpha-msh 11-13 | Not FDA-approved · advisory vote July 2026 · no FDA decision | Not FDA-approved | No category since 2026-04-22 (nomination withdrawn); PCAC recommended 2026-07-23/24; no proposed rule as of 2026-10-04 (as of October 4, 2026) | 2026-07-23: recommended 8-6-1 (free base and acetate; uses reviewed: wound healing, inflammatory conditions; count as read into FDA's meeting recording; written minutes not posted as of 2026-10-04); FDA staff: against | Not recorded | ||
| L-Carnitine (levocarnitine)l-carnitine, l carnitine, levocarnitine, l-carnitine injection | FDA-approved (Rx) | Approved Rx as levocarnitine (Carnitor tablets NDA018948 1985, oral solution NDA019257 1986, injection NDA020182 1992; generics); also sold as a dietary supplement | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not named | ||
| L-Carnosinecarnosine, l-carnosine | Not FDA-approved | Not FDA-approved (as a drug) | Category 3; 503B Category 3; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not recorded | ||
| Lanreotidelanreotide, somatuline depot | FDA-approved (Rx) | Approved Rx (Somatuline Depot NDA022074, 2007) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Leuprolideleuprolide, leuprorelin, lupron, lupron depot, eligard, fensolvi, camcevi | FDA-approved (Rx) | Approved Rx (Lupron NDA019010 1985, Disc; Lupron Depot NDA019732; others) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | S2.2.1 (males) | ||
| LGD-4033 (ligandrol)lgd-4033, lgd4033, lgd 4033, ligandrol, vk5211, anabolicum | Not FDA-approved | Not FDA-approved; excluded from the dietary supplement definition under 201(ff)(3) (FDA ingredient directory categories 2, 4) | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | S1.2 (named LGD-4033 (ligandrol)) | ||
| Linaclotidelinaclotide, linzess | FDA-approved (Rx) | Approved Rx (Linzess NDA202811, 2012) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Liraglutideliraglutide, generic liraglutide, xultophy | FDA-approved (Rx) | Approved Rx (Victoza NDA022341 2010; Saxenda NDA206321 2014; generic ANDA215503 2024) | Approved-drug component; liraglutide injection 'Currently in Shortage' on FDA DSP (checked 2026-10-04); no enforcement-discretion window found (as of October 4, 2026) | Not recorded | Not recorded | ||
| Livagen (Lys-Glu-Asp-Ala)livagen, lys-glu-asp-ala | Not FDA-approved | Not FDA-approved (no drugsfda/DailyMed record) | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not named; S0 (non-approved substances) applies if no health authority approves it for human use | ||
| LL-37 (cathelicidin)ll-37, ll37, ll 37, cathelicidin, cathelicidin ll-37 | Not FDA-approved | Not FDA-approved | No category (nomination withdrawn; removed from Cat 2 2026-04-22); not on 216.23 as of 2026-10-07; not an approved-drug component (as of October 7, 2026) | Scheduled: PCAC 'before the end of February 2027' (no date set) | Not recorded | ||
| Low-dose naltrexone (LDN)ldn, low dose naltrexone, low-dose naltrexone | Not FDA-approved for this use | Approved Rx for naltrexone alone only as tablets (ReVia NDA018932 1984, disc.; generic 50 mg ANDAs; SpecGx ANDA076264 also lists 25 and 100 mg) and Vivitrol NDA021897 2006; no naltrexone-alone product below 25 mg is approved. Contrave NDA200063 2014 pairs naltrexone 8 mg with bupropion 90 mg per tablet for weight management (not a low-dose naltrexone product). Low dose is compounded/off-label. No FDA statement on LDN found | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not named | ||
| Macimorelinmacimorelin, macrilen | FDA-approved (Rx) | Approved Rx (Macrilen NDA205598, 2017); Drugs@FDA lists Disc | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | S2.2.4 | ||
| Maridebart cafraglutide (MariTide)maridebart cafraglutide, maritide, amg 133, cafraglutide | Investigational (phase 3) | Investigational, phase 3 (MARITIME), not filed | No category; not on 216.23 as of 2026-10-07; not an approved-drug component (as of October 7, 2026) | Not recorded | Not recorded | ||
| Matrixyl (palmitoyl pentapeptide-4)matrixyl, palmitoyl pentapeptide-4, palmitoyl pentapeptide, pal-kttks | Cosmetic | Cosmetic | Not recorded | Not recorded | Not recorded | ||
| Mazdutidemazdutide, ibi362, ly3305677 | Not FDA-approved | Not FDA-approved; no US phase 3 or filing (China trials) | No category; not on 216.23 as of 2026-10-07; not an approved-drug component (as of October 7, 2026) | Not recorded | Not recorded | ||
| Mecaserminmecasermin, increlex, igf-1, rhigf-1 | FDA-approved (Rx) | Approved Rx (Increlex BLA021839, 2005) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | S2.3 | ||
| Mechano growth factor (MGF)mgf, mechano growth factor, igf-1ec | Not FDA-approved | Not FDA-approved | Category 3 (since 2023-09-29); not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | S2.3 | ||
| Melanotan IImelanotan 2, melanotan ii, mt2, mt-2, mt-ii, tanning peptide | Not FDA-approved | Not FDA-approved | No category (nomination withdrawn; removed from Cat 2 2026-04-22); not on 216.23 as of 2026-10-07; not an approved-drug component (as of October 7, 2026) | Scheduled: PCAC 'before the end of February 2027' (no date set) | Not recorded | ||
| Metforminmetformin, metformin hydrochloride, glucophage, glucophage xr, metformin er, metformin longevity, metformin for aging | FDA-approved (Rx) | Approved Rx (Glucophage NDA020357 1995, disc.; 200+ ANDAs); label: type 2 diabetes. Boxed warning: lactic acidosis | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not named on the 2026 List | ||
| Methylcobalamin injection (methyl B12)methylcobalamin, methyl b12, methylcobalamin injection, methyl b12 shot, mecobalamin | Not FDA-approved · advisory vote June 2021 · no FDA decision | Not FDA-approved as a drug (openFDA: no application) | Category 1 (503A); PCAC recommended 2021-06-09 (9-5; FDA staff: against); no proposed rule as of 2026-10-07; 503B Category 1 (as of October 7, 2026) | PCAC 2021-06-09: 9-5 for; FDA staff: against | Not named | ||
| Methylene blue (as longevity product)methylene blue, methylene blue longevity, methylene blue drops, provayblue | Not FDA-approved for this use | Approved Rx only as IV injection for acquired methemoglobinemia (ProvayBlue; generics) | Not recorded | Not recorded | Not recorded | ||
| MIC / lipo injection (methionine + inositol + choline, +/- B12)mic injection, mic b12, lipo injection, lipo b, lipo b12, lipotropic injection, lipo shot, skinny shot, mic shot | Not FDA-approved | No approved product; no FDA statement or warning letter found | Choline chloride Category 1 (PCAC 2021 2-11-1 against); methionine no category; inositol no category (only inositol hexanicotinate, Category 3): no verified 503A path; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not named | ||
| MOTS-cmots-c, mots c, motsc, motc, mots c peptide, mitochondrial peptide | Not FDA-approved · advisory vote July 2026 · no FDA decision | Not FDA-approved | No category since 2026-04-22 (nomination withdrawn); PCAC recommended 2026-07-23/24; no proposed rule as of 2026-10-04 (as of October 4, 2026) | 2026-07-23: recommended 7-5-2 (free base and acetate; uses reviewed: obesity, osteoporosis; count as read into FDA's meeting recording; written minutes not posted as of 2026-10-04); FDA staff: against | S4.4.1 | ||
| Mounjaromounjaro, mounjaro kwikpen | FDA-approved (Rx) | Approved Rx (NDA215866, 2022; type 2 diabetes; cardiovascular risk reduction in adults with type 2 diabetes at high risk for major adverse cardiovascular events) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| N-Acetyl Selank (incl. amidate)n-acetyl selank, na-selank, n-acetyl selank amidate, acetyl selank | Not FDA-approved | Not FDA-approved (no drugsfda/DailyMed record) | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not named; S0 (non-approved substances) applies if no health authority approves it for human use | ||
| N-Acetyl Semaxn-acetyl semax, na-semax, acetyl semax | Not FDA-approved | Not FDA-approved (no drugsfda/DailyMed record) | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not named; S0 (non-approved substances) applies if no health authority approves it for human use | ||
| N-Acetyl Semax Amidaten-acetyl semax amidate, na-semax-amidate, semax amidate, nasa peptide | Not FDA-approved | Not FDA-approved (no drugsfda/DailyMed record) | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not named; S0 (non-approved substances) applies if no health authority approves it for human use | ||
| NAC (N-acetylcysteine)nac, n-acetylcysteine, n-acetyl cysteine | Supplement | Dietary supplement under FDA enforcement discretion | Not recorded | Not recorded | Not recorded | ||
| NAD+ (nicotinamide adenine dinucleotide)nad, nad+, nicotinamide adenine dinucleotide | Supplement | Dietary supplement (DSHEA) when oral; injectable is the nad-injectable row | Not recorded | Not recorded | Not recorded | ||
| NAD+ (oral precursors)nad supplement, nad precursor, nad+ supplement | Supplement | Dietary supplement (DSHEA) | Not recorded | Not recorded | Not recorded | ||
| NAD+ injections (Rx)nad injection, nad+ injection, nad iv, nad shots, nad+ iv drip | Not FDA-approved | Not FDA-approved | Category 1 (interim; enforcement discretion) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Naltrexonenaltrexone, naltrexone tablets, vivitrol | FDA-approved (Rx) | Approved Rx (ReVia NDA018932 1984, disc.; generic 50 mg tablets; Vivitrol NDA021897 2006, extended-release injection; with bupropion in Contrave NDA200063 2014) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not named | ||
| NMN (nicotinamide mononucleotide)nmn, nicotinamide mononucleotide, nmn supplement | Supplement | Dietary supplement (DSHEA) | Not recorded | Not recorded | Not recorded | ||
| Noopept (omberacetam)noopept, omberacetam, noopept powder | Not FDA-approved | Not FDA-approved; FDA WL 557887 (2019): Noopept is 'not [a] dietary supplement' | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not named | ||
| NR (nicotinamide riboside)nicotinamide riboside, nr, niagen, tru niagen | Supplement | Dietary supplement (DSHEA) | Not recorded | Not recorded | Not recorded | ||
| Octreotideoctreotide, sandostatin, sandostatin lar, mycapssa, bynfezia | FDA-approved (Rx) | Approved Rx (Sandostatin NDA019667, 1988; LAR; oral Mycapssa) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Oral minoxidil (low-dose)oral minoxidil, minoxidil tablets, low dose oral minoxidil, loniten | Not FDA-approved for this use | Approved Rx (prescription only) as tablets for severe high blood pressure only. The first brand, Loniten (approved 1979), has been discontinued; generic tablets are approved. The label has a boxed warning, the most serious kind. Using it for hair loss is off-label, meaning not an approved use. Minoxidil for the scalp (Rogaine) is sold without a prescription and is a different product | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not named | ||
| Orforglipronorforglipron, lilly glp-1 pill, ly3502970 | FDA-approved (Rx) | Approved Rx (Foundayo NDA220934, 2026-04-01) | Approved-drug component (small molecule; not a peptide) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Ostarine (enobosarm, MK-2866)ostarine, enobosarm, mk-2866, mk2866, mk 2866, gtx-024, ostabolic | Not FDA-approved | Not FDA-approved (openFDA: no application); excluded from the dietary supplement definition under 201(ff)(3) (FDA ingredient directory categories 2, 4) | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | S1.2 (named enobosarm (ostarine)) | ||
| Ovagen (peptide bioregulator)ovagen peptide, ovagen | Not FDA-approved | Not FDA-approved (no drugsfda/DailyMed record) | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not named; S0 (non-approved substances) applies if no health authority approves it for human use | ||
| Oxytocinoxytocin, pitocin | FDA-approved (Rx) | Approved Rx (Pitocin NDA018261, 1980) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Ozempicozempic, ozempic pen, ozempic tablets, ozempic pill | FDA-approved (Rx) | Approved Rx (NDA209637, 2017; tablets NDA213051, 2026; type 2 diabetes; cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease, injection; cardiovascular risk reduction in adults with type 2 diabetes at high risk for major adverse cardiovascular events, tablets; reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, injection only) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| P021 (P21 peptide)p021, p21 peptide, p-21 peptide, p21 nootropic | Not FDA-approved | Not FDA-approved (no drugsfda/DailyMed record) | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not named; S0 (non-approved substances) applies if no health authority approves it for human use | ||
| Palopegteriparatidepalopegteriparatide, yorvipath | FDA-approved (Rx) | Approved Rx (Yorvipath NDA216490, 2024) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Pancragen (Lys-Glu-Asp-Trp)pancragen, lys-glu-asp-trp | Not FDA-approved | Not FDA-approved (no drugsfda/DailyMed record) | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not named; S0 (non-approved substances) applies if no health authority approves it for human use | ||
| Pasireotidepasireotide, signifor, signifor lar | FDA-approved (Rx) | Approved Rx (Signifor NDA200677, 2012; LAR NDA203255) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| PE-22-28pe-22-28, pe 22 28, pe-22-28 peptide | Not FDA-approved | Not FDA-approved (no drugsfda record) | No category; not on 216.23 as of 2026-10-07; not an approved-drug component (as of October 7, 2026) | Not recorded | Not named; S0 (non-approved substances) applies if no health authority approves it for human use | ||
| PEG-MGFpeg-mgf, peg mgf, pegylated mgf, pegylated mechano growth factor | Not FDA-approved | Not FDA-approved | No category (nomination withdrawn; removed from Cat 2 2026-04-22); not on 216.23 as of 2026-10-07; not an approved-drug component (as of October 7, 2026) | Scheduled: PCAC 'before the end of February 2027' (no date set) | S2.3 | ||
| Pentadeca arginate (PDA)pentadeca arginate, pda, pda peptide | Not FDA-approved | Not FDA-approved | No category; not on 216.23 as of 2026-10-07; not an approved-drug component (as of October 7, 2026) | Not recorded | Not recorded | ||
| Pinealon (Glu-Asp-Arg)pinealon, pinealon peptide, edr peptide | Not FDA-approved | Not FDA-approved (no drugsfda/DailyMed record) | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not named; S0 (non-approved substances) applies if no health authority approves it for human use | ||
| Plecanatideplecanatide, trulance | FDA-approved (Rx) | Approved Rx (Trulance NDA208745, 2017) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| PNC-27pnc-27, pnc 27, pnc-27 peptide | Not FDA-approved | Not FDA-approved (no drugsfda record) | No category; not on 216.23 as of 2026-10-07; not an approved-drug component (as of October 7, 2026) | Not recorded | Not named; S0 (non-approved substances) applies if no health authority approves it for human use | ||
| Pramlintidepramlintide, symlin, symlinpen, amylin analog | FDA-approved (Rx) | Approved Rx (Symlin NDA021332, 2005); manufacture discontinued (AstraZeneca, FDA drug shortage list, posted 2025-10-27); Drugs@FDA lists every strength Discontinued; listed marketing end date 2027-01-31 | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Pregnenolonepregnenolone, pregnenolone micronized | Supplement | Not an approved drug; sold OTC as a dietary supplement | Category 1 (503A); 503B Category 3 (as of May 14, 2026) | Not recorded | Not named | ||
| Progesterone (incl. oral micronized)progesterone, prometrium, micronized progesterone, oral micronized progesterone, progesterone in oil, crinone, endometrin, bioidentical progesterone | FDA-approved (Rx) | Approved Rx (Prometrium NDA019781 1998; progesterone-in-oil ANDAs) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not named | ||
| Prostamax (Lys-Glu-Asp-Pro)prostamax, prostamaxin, lys-glu-asp-pro | Not FDA-approved | Not FDA-approved (no drugsfda/DailyMed record) | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not named; S0 (non-approved substances) applies if no health authority approves it for human use | ||
| PTD-DBM (topical hair peptide)ptd-dbm, ptd dbm | Not FDA-approved | Not FDA-approved (no drugsfda/DailyMed record) | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not named; S0 (non-approved substances) applies if no health authority approves it for human use | ||
| RAD-140 (testolone)rad-140, rad140, rad 140, testolone, vosilasarm | Not FDA-approved | Not FDA-approved; FDA: SARMs 'cannot be legally marketed in the U.S. as a dietary supplement or drug' | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | S1.2 (named RAD140) | ||
| Rapamycin (sirolimus)rapamycin, sirolimus, rapamune, rapa, rapamycin longevity, low dose rapamycin, fyarro, hyftor | FDA-approved (Rx) | Approved Rx (Rapamune NDA021083 1999 / NDA021110 2000; Fyarro NDA213312 2021; Hyftor gel; generics); label: renal-transplant rejection prophylaxis. Boxed warning. Longevity use is off-label | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not named | ||
| Retatrutideretatrutide, reta, retatrutide peptide, ly3437943, glp-3, triple g | Investigational (phase 3) | Investigational, phase 3, not filed (Lilly plans BLA Q1 2027) | Not eligible (FDA: 'cannot be used in compounding under federal law') (as of October 1, 2026) | Not recorded | Not recorded | ||
| Retatrutide / MOTS-c stackretatrutide mots-c, elite metabolic stack, metabolic super stack | Not FDA-approved | Not FDA-approved as a combination | No category as a combination (see components) | Not recorded | Not recorded | ||
| Romiplostimromiplostim, nplate | FDA-approved (Rx) | Approved Rx (Nplate BLA125268, 2008) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Rybelsusrybelsus | FDA-approved (Rx) | Approved Rx (NDA213051, 2019; type 2 diabetes; cardiovascular risk reduction in adults with type 2 diabetes at high risk for major adverse cardiovascular events) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Saxendasaxenda | FDA-approved (Rx) | Approved Rx (NDA206321, 2014; weight management) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Secretin, humansecretin, human secretin | FDA-approved (Rx) | Approved Rx (ChiRhoStim, synthetic human secretin; NDA021256, 2004; diagnostic) | Category 3 (since 2023-09-29); 503B Category 3 (as of May 14, 2026) | Not recorded | Not recorded | ||
| Selankselank, selank acetate, tp-7 | Not FDA-approved | Not FDA-approved | No category (removed from Cat 2 2024-09-27: nominator meant a different substance); not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not recorded | ||
| Semaglutidesemaglutide, sema | FDA-approved (Rx) | Approved Rx (Ozempic NDA209637 2017; Wegovy NDA215256 2021; Rybelsus NDA213051 2019; Ozempic tablets NDA213051 2026; Wegovy tablet NDA218316 2025) | Approved-drug component; shortage resolved 2025-02-21 (503A window ended, PI denied 2025-04-24; 503B ended 2025-05-22); 'essentially a copy' limits apply (as of April 1, 2026) | Not recorded | Not prohibited (monitoring) | ||
| Semaglutide / AOD-9604 stacksemaglutide aod-9604, sema aod | Not FDA-approved | Not FDA-approved as a combination | No category as a combination (see components) | Not recorded | Not recorded | ||
| Semaglutide sodium / acetate (salt forms)semaglutide sodium, semaglutide acetate, semaglutide salt | Not FDA-approved | Not FDA-approved | FDA: 'not aware of any lawful basis for their use in compounding' (as of October 1, 2026) | Not recorded | Not prohibited (monitoring) | ||
| Semaxsemax, semax peptide, semax heptapeptide | Not FDA-approved · advisory vote July 2026 · no FDA decision | Not FDA-approved | No category since 2026-04-22 (nomination withdrawn); PCAC recommended 2026-07-23/24; no proposed rule as of 2026-10-04 (as of October 4, 2026) | 2026-07-24: recommended 8-5-1 (free base and acetate; uses reviewed: cerebral ischemia, migraine, trigeminal neuralgia; count as read into FDA's meeting recording; written minutes not posted as of 2026-10-04); FDA staff: against | Not recorded | ||
| Semax / selank stacksemax selank, semax selank stack, russian nootropic stack, russian stack | Not FDA-approved | Not FDA-approved as a combination | No category as a combination (see components) | Not recorded | Not recorded | ||
| Sermorelinsermorelin, sermorelin acetate, geref, grf 1-29 | FDA-approved, discontinued | Approved 1990 (Geref NDA019863/NDA020443), discontinued; Drugs@FDA: FR determination not withdrawn for safety or effectiveness | No 503A category; 503B Category 1 as approved-drug component (as of March 21, 2025) | Not recorded | S2.2.4 | ||
| Sermorelin / GHRP-2 stacksermorelin ghrp-2, sermorelin ghrp2 | Not FDA-approved | Not FDA-approved as a combination | No category as a combination (see components) | Not recorded | Not recorded | ||
| Setmelanotidesetmelanotide, imcivree | FDA-approved (Rx) | Approved Rx (Imcivree NDA213793, 2020) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Sildenafilsildenafil, sildenafil citrate, viagra, revatio, generic viagra | FDA-approved (Rx) | Approved Rx (Viagra NDA020895 1998; Revatio NDA021845 2005; generics); label: ED (Viagra), PAH (Revatio) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not named | ||
| SLU-PP-332slu-pp-332, slu pp 332, slu-pp-332 peptide, slupp332 | Not FDA-approved | Not FDA-approved (no drugsfda record) | No category; not on 216.23 as of 2026-10-07; not an approved-drug component (as of October 7, 2026) | Not recorded | Not named; S0 (non-approved substances) applies if no health authority approves it for human use | ||
| SNAP-8 (cosmetic peptide)snap-8, snap 8, snap8, snap-8 peptide | Not FDA-approved | Not FDA-approved (no drugsfda record) | No category; not on 216.23 as of 2026-10-07; not an approved-drug component (as of October 7, 2026) | Not recorded | Not named; S0 (non-approved substances) applies if no health authority approves it for human use | ||
| Somatropin (HGH)somatropin, hgh, human growth hormone, growth hormone, genotropin, norditropin, somatotropin | FDA-approved (Rx) | Approved Rx (multiple BLAs; e.g. Genotropin, Norditropin) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | S2.2.3 | ||
| Spermidinespermidine, spermidine trihydrochloride, wheat germ spermidine | Supplement | Not an approved drug; sold as a dietary supplement (GRAS notice GRN 889 closed at notifier's request 2020) | Not recorded | Not recorded | Not named | ||
| Survodutidesurvodutide, bi 456906 | Investigational (phase 3) | Investigational, phase 3, no US submission found | No category; not on 216.23 as of 2026-10-07; not an approved-drug component (as of October 7, 2026) | Not recorded | Not recorded | ||
| Tadalafiltadalafil, cialis, adcirca, daily cialis, tadalafil troche | FDA-approved (Rx) | Approved Rx (Cialis NDA021368 2003; Adcirca NDA022332 2009; generics); label: ED, BPH | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not named | ||
| Taurinetaurine | Supplement | Dietary supplement (DSHEA) | Not recorded | Not recorded | Not recorded | ||
| TB-500 (thymosin beta-4 fragment LKKTETQ)tb-500, tb500, tb 500, thymosin beta-4 fragment, lkktetq, thymosin beta 4 fragment | Not FDA-approved · advisory vote July 2026 · no FDA decision | Not FDA-approved | No category since 2026-04-22 (nomination withdrawn); PCAC recommended 2026-07-23/24; no proposed rule as of 2026-10-04 (as of October 4, 2026) | 2026-07-23: recommended 8-6-1 (free base and acetate; use reviewed: wound healing; count as read into FDA's meeting recording; written minutes not posted as of 2026-10-04); FDA staff: against | S2.3 | ||
| Teduglutideteduglutide, gattex, glp-2 analog | FDA-approved (Rx) | Approved Rx (Gattex NDA203441, 2012) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Teriparatideteriparatide, forteo, bonsity, pth 1-34 | FDA-approved (Rx) | Approved Rx (Forteo NDA021318, 2002; generics) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Tesamorelintesamorelin, tesa | FDA-approved (Rx) | Approved Rx (Egrifta BLA022505, 2010; current Egrifta WR) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | S2.2.4 | ||
| Tesamorelin / ipamorelin stacktesamorelin ipamorelin, tesa ipa, tesa/ipa, tesa ipa blend | Not FDA-approved | Not FDA-approved as a combination | No category as a combination (see components) | Not recorded | Not recorded | ||
| Tesofensinetesofensine, tesofensine peptide, ns2330 | Not FDA-approved | Not FDA-approved (no drugsfda record) | No category; not on 216.23 as of 2026-10-07; not an approved-drug component (as of October 7, 2026) | Not recorded | S6.b (named Tesofensine) | ||
| Testagentestagen, lys-glu-asp-gly | Not FDA-approved | Not FDA-approved (no drugsfda/DailyMed record) | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not named; S0 (non-approved substances) applies if no health authority approves it for human use | ||
| Testosterone (cypionate, enanthate, gels, undecanoate)testosterone, trt, testosterone replacement therapy, testosterone cypionate, test cyp, testosterone enanthate, test e, testosterone gel, testosterone cream, testosterone injection, testosterone undecanoate, depo-testosterone, xyosted, androgel, aveed, jatenzo, kyzatrex | FDA-approved (Rx) | Approved Rx (Depo-Testosterone ANDA085635; AndroGel NDA021015 2000; Xyosted NDA209863 2018; many ANDAs); label: male hypogonadism; delayed puberty in males (generic testosterone enanthate injection, not Xyosted). DEA Schedule III | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | S1.1 (named Testosterone) | ||
| Thymalinthymalin, thymaline, timalin, tymalin | Approved outside the US | Not FDA-approved (no drugsfda/DailyMed record) | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not named; approved in Russia, so S0 does not apply | ||
| Thymogen (oglufanide, Glu-Trp)thymogen, timogen, oglufanide, glutamyl-tryptophan | Approved outside the US | Not FDA-approved (no drugsfda/DailyMed record) | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not named; approved in Russia, so S0 does not apply | ||
| Thymopentin (TP-5)thymopentin, tp-5, tp5, timunox | Not FDA-approved | Not FDA-approved (no drugsfda/DailyMed record) | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not named; S0 (non-approved substances) applies if no health authority approves it for human use | ||
| Thymosin alpha-1thymosin alpha 1, thymosin alpha-1, ta1, ta-1, thymalfasin, zadaxin | Approved outside the US | Not FDA-approved (openFDA thymalfasin: no records) | No category (nomination withdrawn; removed from Cat 2 2024-09-27); not on 216.23 as of 2026-10-07; not an approved-drug component; 503B Category 3 (as of October 7, 2026) | 2024-12-04: against 4-17-0 (free base and acetate; uses reviewed incl. hepatitis B/C, HIV, cancers); FDA staff: against | Not recorded | ||
| Thymosin alpha-1 / LL-37 stackta1 ll-37, immune resilience stack | Not FDA-approved | Not FDA-approved as a combination | No category as a combination (see components) | Not recorded | Not recorded | ||
| Thymosin beta-4 (full-length)thymosin beta-4, thymosin beta 4, tb4, tβ4 | Not FDA-approved | Not FDA-approved | Not listed; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not voted; PCAC 2026-07-23 covered the LKKTETQ fragment (TB-500) only | S2.3 | ||
| Thymulinthymulin, thymulin acetate | Not FDA-approved | Not FDA-approved | Category 3 (since 2023-09-29); not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not recorded | ||
| Tirzepatidetirzepatide, tirz | FDA-approved (Rx) | Approved Rx (Mounjaro NDA215866 2022; Zepbound NDA217806 2023) | Approved-drug component; shortage resolved 2024-12-19 (503A window ended, PI denied 2025-03-05; 503B ended 2025-03-19); 'essentially a copy' limits apply (as of April 1, 2026) | Not recorded | Not prohibited (monitoring) | ||
| TMG (betaine)tmg, trimethylglycine, betaine | Supplement | Dietary supplement (DSHEA) | Not recorded | Not recorded | Not recorded | ||
| Triptorelintriptorelin, trelstar, triptodur | FDA-approved (Rx) | Approved Rx (Trelstar NDA020715, 2000; Triptodur) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | S2.2.1 (males) | ||
| Urolithin Aurolithin a, mitopure | Supplement | Dietary supplement (DSHEA) | Not recorded | Not recorded | Not recorded | ||
| Vasoactive intestinal peptide (VIP)vip, vasoactive intestinal peptide, vip peptide, aviptadil | Not FDA-approved | Not FDA-approved | Category 1 (interim; enforcement discretion); not on 216.23 as of 2026-10-07 (as of October 7, 2026) | 2016-11-03: voted not to include (vote count not confirmed), FDA proposed exclusion 2019-09-05 (84 FR 46688), never finalized | Not recorded | ||
| Vasopressinvasopressin, vasostrict, adh, antidiuretic hormone | FDA-approved (Rx) | Approved Rx (Vasostrict NDA204485, 2014) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Vesugen (Lys-Glu-Asp)vesugen, lys-glu-asp | Not FDA-approved | Not FDA-approved (no drugsfda/DailyMed record) | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not named; S0 (non-approved substances) applies if no health authority approves it for human use | ||
| Victozavictoza | FDA-approved (Rx) | Approved Rx (NDA022341, 2010; type 2 diabetes; cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Vilon (Lys-Glu)vilon, lys-glu, lysylglutamic acid | Not FDA-approved | Not FDA-approved (no drugsfda/DailyMed record) | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | Not named; S0 (non-approved substances) applies if no health authority approves it for human use | ||
| Vitamin B12 injection (cyanocobalamin / hydroxocobalamin)b12 injection, b12 shot, vitamin b12 injection, cyanocobalamin, cyanocobalamin injection, hydroxocobalamin, nascobal | FDA-approved (Rx) | Approved Rx (cyanocobalamin injection ANDA080737 and others; hydroxocobalamin ANDA085998; Cyanokit NDA022041); label: B12 deficiency, pernicious anemia | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not named | ||
| Vosoritidevosoritide, voxzogo | FDA-approved (Rx) | Approved Rx (Voxzogo NDA214938, 2021) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Vyleesivyleesi | FDA-approved (Rx) | Approved Rx (NDA210557, 2019; HSDD in premenopausal women) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Wegovywegovy, wegovy pen, wegovy pill, wegovy tablet | FDA-approved (Rx) | Approved Rx (NDA215256, 2021; tablet NDA218316, 2025; chronic weight management; cardiovascular risk reduction; noncirrhotic MASH with moderate to advanced liver fibrosis (stages F2 to F3) in adults, injection only, under accelerated approval) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Wolverine stack (BPC-157 + TB-500)wolverine stack, wolverine peptide, bpc tb500 stack, bpc-157 tb-500 blend, bpc + tb500 | Not FDA-approved | Not FDA-approved | No category since 2026-04-22 (nomination withdrawn); PCAC recommended 2026-07-23/24; no proposed rule as of 2026-10-04 (as of October 4, 2026) | Components each recommended 8-6-1 on 2026-07-23; the blend itself was not voted | S0 (BPC-157); S2.3 (TB-500) | ||
| YK-11yk-11, yk11, yk 11, ykarine | Not FDA-approved | Not FDA-approved; FDA ingredient directory category 2; named in FDA fraudulent-products notice (GE Labs Ykarine) | No category; not on 216.23 as of 2026-10-07 (as of October 7, 2026) | Not recorded | S1.2 (named YK-11) | ||
| Zepboundzepbound, zepbound vial, zepbound kwikpen | FDA-approved (Rx) | Approved Rx (NDA217806, 2023; weight management; OSA with obesity) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded | ||
| Ziconotideziconotide, prialt | FDA-approved (Rx) | Approved Rx (Prialt NDA021060, 2004) | Approved-drug component (not in any 503A category) (as of May 14, 2026) | Not recorded | Not recorded |
Download the data
Licensed under CC BY 4.0. Version 2026.10.14 (commit 56e4520) · as of October 12, 2026 · 210 rows · Ellum, Peptide Access Index
Fields: id, canonical_name, aliases, status_label, status_class, trial_phase, fda_status, compounding_503a, compounding_as_of, pcac_history, wada_2026, prescribable_today, as_of, source_urls, class, mechanism, url, status_key, row_id, version, attribution
Cite this page: Ellum, Peptide Access Index, https://ellumclinic.com/peptides/status, data as of 2026-10-12.